The US Food and Drug Administration should force an OTC switch of beta-2 antagonist asthma inhalers if manufacturers don’t submit proposals, asthma treatment researchers recommend.
In addition to a epinephrine inhaler indicated for emergency use which the FDA currently allows for nonprescription access, a “positive step forward would be to make inhaled albuterol available OTC,” say William Feldman and his colleagues at the Brigham and Women's Hospital Division of Pulmonary
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?